Indivior Plc - Company Profile
Powered by
All the data and insights you need on Indivior Plc in one report.
- Save hours of research time and resources with
our up-to-date Indivior Plc Strategy Report
- Understand Indivior Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Indivior Plc (Indivior) develops, manufactures, and sells buprenorphine-based prescription pharmaceuticals for the treatment of opioid dependence. The company offers buprenorphine-based injectable for the treatment of opioid dependence, and buprenorphine-based injectable suspension, for subcutaneous use, for the treatment of schizophrenia. It also offers a nasal spray for the treatment of opioid overdose reversal. Its pipeline portfolio encompasses buprenorphine-based products for substance use disorder; and cannabis disorder. Indivior offers products in the form of film, tablets, injectable suspension and nasal spray. It provides its products in the US, Australia, Malaysia, France, Italy; Spain, Germany, Canada, and the UK. Indivior is headquartered in Slough, England, the UK.
Indivior Plc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Opiod Dependence Drugs: | Subutex |
Suboxone (Sublingual Film/Sublingual Tablet) | Suboxone |
Subutex (Sublingual Tablet) | Sublocade |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In December, Indivior Inc. along with Indivior UK Limited entered into a settlement agreement with Actavis Laboratories UT to resolve patent disputes of Actavis's Abbreviated New Drug Application for generic buprenorphine and naloxone sublingual film. |
2023 | Corporate Changes/Expansions | In November, the company announced its plans to invest US$60 million in the Raleigh manufacturing plant. |
2023 | Contracts/Agreements | In October, the company secured an exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.’s portfolio of long-acting injectable formulations. |
Competitor Comparison
Key Parameters | Indivior Plc | AstraZeneca Plc | Vernalis R&D Ltd | Cassava Sciences Inc | GW Pharmaceuticals Ltd |
---|---|---|---|---|---|
Headquarters | United Kingdom | United Kingdom | United Kingdom | United States of America | United Kingdom |
City | Slough | Cambridge | Cambridge | Austin | Cambridge |
State/Province | Berkshire | England | England | Texas | England |
No. of Employees | 1,051 | 89,900 | - | 29 | - |
Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Graham Hetherington | Chairman | Executive Board | 2020 | 65 |
Mark Crossley | Chief Executive Officer; Director | Executive Board | 2020 | 54 |
Ryan Preblick | Director; Chief Financial Officer | Executive Board | 2020 | 48 |
Jeffrey Burris | Chief Legal Officer | Senior Management | 2021 | 52 |
Cynthia Cetani | Chief Integrity Officer; Chief Compliance Officer | Senior Management | 2018 | 58 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer